• Tunicamycin: Applied Workflows for N-Glycosylation Inhibitio

  2026-05-31

  Tunicamycin from APExBIO is the gold-standard N-glycosylation inhibitor, enabling robust modeling of endoplasmic reticulum (ER) stress and inflammation suppression in cellular and in vivo systems. This article delivers data-driven workflow enhancements, troubleshooting guidance, and actionable insights—translating recent breakthroughs into reproducible, high-impact experimental design.

• Paroxetine Mesylate: Molecular Targeting Beyond SSRI Activit

  2026-05-30

  Explore Paroxetine Mesylate as a selective serotonin reuptake inhibitor with unique multi-kinase and cytochrome P450 inhibition, expanding its value in research beyond classic antidepressant roles. This article delivers a rigorous molecular analysis and practical assay insight for advanced translational workflows.

• Dihydrotestosterone (DHT): Protocols for AR and EGFR Pathway

  2026-05-29

  Dihydrotestosterone (DHT) unlocks precise control over androgen receptor and growth factor signaling in cancer, neurodegeneration, and muscle research. This guide translates recent breakthroughs into actionable protocols, troubleshooting guidance, and comparative insights for optimizing your research with APExBIO’s DHT.

• Z-VAD-FMK: Pan-Caspase Inhibitor for Apoptosis Pathway Resea

  2026-05-29

  Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor widely used to dissect apoptotic signaling in both in vitro and in vivo studies. Its established specificity for caspase blockade enables precise apoptosis inhibition in research, as demonstrated by robust evidence in immune and cancer models.

• Esflurbiprofen Blocks SERT-nNOS for Rapid Antidepressant Eff

  2026-05-28

  The reference study introduces esflurbiprofen as a novel fast-onset antidepressant, acting by disrupting the SERT-nNOS interaction in the dorsal raphe nucleus. This mechanistic advance over conventional SSRIs provides a new avenue for antidepressant development with improved therapeutic onset.

• BMS-777607: Advanced c-Met Inhibitor Workflows for Platelet

  2026-05-28

  BMS-777607, a potent c-Met inhibitor from APExBIO, is redefining experimental precision in both cancer metastasis modeling and hiPSC-derived platelet workflows. This article details protocol enhancements, application bridges, and troubleshooting tactics, drawing from the latest literature to maximize reproducibility and yield.

• Calcitriol and VDR Signaling: Bench to Reproductive Biology

  2026-05-27

  Explore how Calcitriol, a key 1,25-dihydroxy vitamin D3 metabolite, advances reproductive research by unlocking new mechanistic insights into endometrial decidualization and immune modulation. This article uniquely connects advanced VDR pathway findings to practical assay and workflow design.

• FK866 (APO866): Precision NAMPT Inhibition in Cancer Researc

  2026-05-27

  FK866 (APO866) is redefining cancer biology workflows by selectively targeting NAD biosynthesis with nanomolar potency. Recent reference studies demonstrate how combining FK866 with PARP inhibitors leverages metabolic vulnerabilities in RAS/PI3K-mutant ovarian and hematologic cancers, unlocking new avenues for selective cytotoxicity and resistance management.

• Humanized Gs-Coupled DREADD Enables Safer Neural Circuit Mod

  2026-05-26

  This study introduces a fully humanized Gs-coupled DREADD (hM3Ds), addressing immunogenicity concerns and demonstrating functional equivalence to rodent models. The innovation expands the translational potential of chemogenetic neuromodulation, with clear implications for both research and clinical applications.

• Clarithromycin as a CYP3A Inhibitor: Advanced Workflows & So

  2026-05-26

  Clarithromycin stands out as a gold-standard CYP3A inhibitor, enabling high-fidelity drug-drug interaction and pharmacokinetic studies—especially in scenarios involving statin and cardiovascular drug metabolism. This guide distills best practices, troubleshooting tips, and the latest evidence for optimizing experimental workflows using APExBIO's Clarithromycin.

• Trelagliptin Succinate: Mechanistic Insights for Insulin Res

  2026-05-25

  Explore how Trelagliptin succinate, a selective DPP-4 inhibitor, improves insulin resistance through nuanced pathway modulation. This article offers advanced protocol guidance and unique mechanistic perspectives for type 2 diabetes research.

• Hypoxia, Immunometabolism, and Redox Regulation in Tumors

  2026-05-25

  This review synthesizes current understanding of how hypoxia and immune metabolic reprogramming shape the tumor microenvironment, driving immunosuppression and tumor progression. By dissecting mechanisms linking oxygen deprivation, metabolic shifts, and immune cell fate, the study outlines both challenges and therapeutic opportunities in targeting tumor immunometabolism.

• mCherry mRNA: Optimizing Red Fluorescent Reporter Workflows

  2026-05-24

  Harness the power of EZ Cap™ mCherry mRNA for robust, immune-evasive fluorescent protein expression in advanced cell assays. Discover practical protocols, troubleshooting strategies, and workflow enhancements that set this reporter gene mRNA apart for translational and imaging applications.

• BMS-777607: Selective c-Met Inhibitor for MET Pathway Resear

  2026-05-23

  BMS-777607 is a potent ATP-competitive c-Met inhibitor with nanomolar selectivity for MET kinase family members. It enables precise modulation of MET signaling in cancer and stem cell models, offering robust evidence for apoptosis and metastasis suppression.

• N1-Methyl-Pseudouridine-5'-Triphosphate: Reliable Modified N

  2026-05-22

  This article presents scenario-driven, evidence-based strategies for addressing core challenges in cell viability, proliferation, and cytotoxicity assays using N1-Methyl-Pseudouridine-5'-Triphosphate (SKU B8049). Leveraging validated literature and best practices, it highlights how the APExBIO product enhances RNA stability, translational efficiency, and reproducibility in demanding experimental contexts.

15806 records 1/1054 page Next 12345 下5页 Last page